{"product_id":"scripps-clinical-hematology-and-oncology-2026","title":"Scripps Clinical Hematology and Oncology 2026","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: hematologists, medical oncologists, and advanced practice providers\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e1. Overview\u003c\/p\u003e\n\u003cp\u003eScripps Cancer Center’s Clinical Hematology and Oncology course is tailored for hematologists, oncologists, surgeons, radiation oncologists, internists, and other health care professionals seeking updates in these specialized areas. The course’s primary objective is to unite clinicians and leading experts across various fields of hematology and oncology in a collaborative and engaging environment to explore the latest clinical advancements and significant breakthroughs. This nationally accredited annual continuing medical education program stands as one of the largest hematology\/oncology conferences in the Western United States, alongside other prominent meetings such as ASH, ASCO, and the San Antonio Breast Cancer Symposium. Notably, this conference is among the few that seamlessly integrates topics from both hematology and oncology, offering a unique and comprehensive educational experience.\u003c\/p\u003e\n\u003cp\u003eCourse Date: 2026\u003c\/p\u003e\n\u003cp\u003e2. Learning Objectives\u003c\/p\u003e\n\u003cp\u003eExplain the clinical and molecular aspects of pathogenesis, diagnostic methods, and treatment options for a range of hematologic disorders.\u003c\/p\u003e\n\u003cp\u003eIdentify and implement evolving approaches to hematologic malignancies, with a focus on evidence-based standards of care and advancements in diagnosis and treatment.\u003c\/p\u003e\n\u003cp\u003eEvaluate and select emerging therapeutic options for managing common malignancies, while considering their appropriate indications and contraindications.\u003c\/p\u003e\n\u003cp\u003eIncorporate evolving approaches to solid tumors and breast cancer from a diagnostic, prognostic, and therapeutic perspective.\u003c\/p\u003e\n\u003cp\u003eUtilize practical insights from the clinical scenarios presented during panel discussions, focusing on evidence-based approaches to managing patients with common yet serious hematology and oncology conditions.\u003c\/p\u003e\n\u003cp\u003e3. Target Audience\u003c\/p\u003e\n\u003cp\u003eBest for hematologists, medical oncologists, and advanced practice providers who want updates on targeted therapies, immunotherapies, and cancer care.\u003c\/p\u003e\n\u003cp\u003e4. Topics\u003c\/p\u003e\n\u003cp\u003e02 ITP 2026 Update\u003c\/p\u003e\n\u003cp\u003e03 Transfusion Medicine for the Practicing Hem-Onc Physician\u003c\/p\u003e\n\u003cp\u003e04 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e05 Unusual Thromboses\u003c\/p\u003e\n\u003cp\u003e06 Anticoagulants and Antiplatelet Agents When to Combine and When not to\u003c\/p\u003e\n\u003cp\u003e07 VTE and Anticoagulation 2026 Update\u003c\/p\u003e\n\u003cp\u003e08 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e09 Breakout 1 Interesting Cases in Thrombosis\u003c\/p\u003e\n\u003cp\u003e10 Breakout 2 Interesting Cases in Platelet Disorders\u003c\/p\u003e\n\u003cp\u003e11 Breakout 3 Interesting Cases in Bleeding\u003c\/p\u003e\n\u003cp\u003e12 Breakout 4 Interesting Cases in Plasma Cell Dyscrasias\u003c\/p\u003e\n\u003cp\u003e13 Melanoma From Neo-Adjuvant Therapy to Refractory Disease Immune Therapy, Novel Agents, and Managing irAEs – Janice Mehnert, MD\u003c\/p\u003e\n\u003cp\u003e13 Melanoma From Neo-Adjuvant Therapy to Refractory Disease Immune Therapy, Novel Agents, and Managing irAEs – Ryan Sullivan, MD\u003c\/p\u003e\n\u003cp\u003e13 Melanoma From Neo-Adjuvant Therapy to Refractory Disease Immune Therapy, Novel Agents, and Managing irAEs -Allison Betof-Warner, MD, PhD\u003c\/p\u003e\n\u003cp\u003e14 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e15 Menin Inhibitors and Other New Targeted Therapies in AML\u003c\/p\u003e\n\u003cp\u003e16 Hypomethylating Agents and Beyond Cutting-Edge Approaches to MDS\u003c\/p\u003e\n\u003cp\u003e17 After IMiDs, Proteosome Inhibitors, and CD38 Antibodies Novel Approaches to RelapsedRefractory Multiple Myeloma\u003c\/p\u003e\n\u003cp\u003e18 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e19 Newer Therapeutic Options for Refractory or Relapsed Large Cell Lymphoma\u003c\/p\u003e\n\u003cp\u003e20 Non-Chemotherapy Approaches to Mantle Cell Lymphoma\u003c\/p\u003e\n\u003cp\u003e21 Progress in the Treatment of AL Amyloidosis\u003c\/p\u003e\n\u003cp\u003e22 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e23 Beyond BRCA Managing Risk in Women with Moderate-Penetrance Gene Mutations\u003c\/p\u003e\n\u003cp\u003e24 Advances in the Treatment of Metastatic Triple-Negative Breast Cancer\u003c\/p\u003e\n\u003cp\u003e25 Minimal Residual Disease, Disease Monitoring, and Therapy Selection What is the Evidence-Based role for ctDNA in Breast Cancer Therapy\u003c\/p\u003e\n\u003cp\u003e26 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e27 Neo-Adjuvant Chemo-Immunotherapy in Resectable NSCLC A New Standard of Care\u003c\/p\u003e\n\u003cp\u003e29 Comparing the Harms and Benefits of Chemo-Immunotherapy or Immunotherapy Alone in the Metastatic Setting\u003c\/p\u003e\n\u003cp\u003e30 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e31 Checkpoint Immune Therapy in the Curative Settings of GI Cancers\u003c\/p\u003e\n\u003cp\u003e32 Are TTFs and Novel Small Molecules Moving the Needle in Pancreatic Cancer\u003c\/p\u003e\n\u003cp\u003e33 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e34 De-Escalation Strategies in HPV Positive Head and Neck Cancer\u003c\/p\u003e\n\u003cp\u003e35 Cervical Cancer Updates\u003c\/p\u003e\n\u003cp\u003e36 Molecular Classification and Treatment Opportunities in Brain Tumors\u003c\/p\u003e\n\u003cp\u003e37 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e\n\u003cp\u003e38 Optimizing Bone Health in Cancer Care During and After Treatment\u003c\/p\u003e\n\u003cp\u003e39 Management of Common Skin Related Side Effects During and After Cancer Treatment\u003c\/p\u003e\n\u003cp\u003e40 Panel DiscussionQ\u0026amp;A\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405751177412,"sku":null,"price":65.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Scripps-Clinical-Hematology-and-Oncology-2026.jpg?v=1784215651","url":"https:\/\/medicalcoursespro.com\/products\/scripps-clinical-hematology-and-oncology-2026","provider":"Medicalcoursespro","version":"1.0","type":"link"}